Form 4: Atara Biotherapeutics CFO Eric J. Hyllengren Sells Shares to Cover Tax Obligations

Eric J. Hyllengren, CFO of Atara Biotherapeutics, sold shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On August 16, 2024, Eric J. Hyllengren, the CFO of Atara Biotherapeutics, sold 1,070 shares of common stock.
• The sales were executed at weighted average prices of $6.629 and $6.631.
• These transactions were conducted to satisfy tax withholding obligations associated with the vesting of previously granted restricted stock units.
• Following the reported transactions, Hyllengren beneficially owns 24,756 shares of Atara Biotherapeutics common stock.
• The reported amount of shares beneficially owned reflects a 1:25 reverse stock split that Atara Biotherapeutics effected on June 20, 2024.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock sales for tax purposes, indicating a neutral sentiment.

Industry Context

Form 4 filings are a routine part of the US stock market, and are required by the SEC to ensure transparency of trading activity by corporate insiders.

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by some shareholders, but the reason for the sale (tax obligations) is a common and generally accepted practice.

Key Dates